文献速递MDS 与骨髓增殖性肿瘤

国产阿扎胞苷治疗较高危MDS的多中心前瞻性单臂研究

[Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究纳入72例中国较高危MDS患者,接受国产阿扎胞苷75 mg·m⁻²·d⁻¹皮下注射7天/28天周期至少6周期。治疗6周期时总缓解率6.9%,最佳CR+PR率12.5%,中位OS 16.1个月,药代动力学与原研一致。

要点

  • 国产阿扎胞苷治疗较高危MDS总缓解率6.9%,最佳CR+PR率12.5%。
  • 基线输血依赖患者中46.3%脱离红细胞输注,41.2%脱离血小板输注。
  • 中位OS 16.1个月,≥6周期者中位OS 22.3个月,安全性可接受。

核心结论

  • 国产阿扎胞苷治疗较高危MDS疗效肯定、安全可靠,药代动力学与原研一致,可作为标准治疗。

研究设计与样本

  • 多中心、前瞻性、单臂研究,2013年10月至2016年10月国内9家中心纳入72例较高危MDS患者。
  • 患者接受国产阿扎胞苷75 mg·m⁻²·d⁻¹皮下注射,7天/28天周期,至少6周期。

主要发现

  • 治疗6周期或提前终止时总缓解率(CR+PR)为6.9%(5/72),治疗期间最佳CR或PR率为12.5%(9/72)。
  • 基线红细胞输血依赖者46.3%(19/41)脱离依赖,血小板输血依赖者41.2%(7/17)脱离依赖。
  • 中位治疗6周期,中位OS 16.1个月(95%CI 10.9-20.6),≥6周期者(36例,50%)中位OS 22.3个月(95%CI 16.1-不可评估)。
  • 最常见Ⅲ~Ⅳ级血液学不良事件:中性粒细胞减少55%、白细胞减少47%、血小板减少61%。
  • 药代动力学参数与原研阿扎胞苷中国数据基本一致。

关键数值与推荐

  • 国产阿扎胞苷剂量75 mg·m⁻²·d⁻¹,皮下注射,持续7天,28天为一周期,至少6周期。
  • 总缓解率(CR+PR)6.9%(5/72),最佳CR或PR率12.5%(9/72)。
  • 中位OS 16.1个月(95%CI 10.9-20.6),≥6周期者中位OS 22.3个月(95%CI 16.1-不可评估)。

临床怎么用

  • 国产阿扎胞苷可按标准方案用于中国较高危MDS患者,疗效与安全性可接受。
  • 治疗中需重点监测Ⅲ~Ⅳ级血液学不良事件,尤其是血小板减少、中性粒细胞减少和白细胞减少。

局限性

  • 单臂研究设计,无对照组。
  • 样本量72例,部分亚组分析样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy, safety, and pharmacokinetics of the generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes(MDS). Methods: Between October 2013 and 2016, 72 patients were eligible for enrollment at 9 sites from China received generic subcutaneous azacitidine 75 mg·m(-2)·d(-1) for 7 days per 28-day cycle, for ≥6 cycles. Pharmacokinetic blood samples were collected on day 1 of a single-dose. Results: For each patient at cycle 6 or at the time of study discontinuation, whichever came first, the overall response rate, which included complete remission (CR)and partial remission(PR), was 6.9%(5/72), the rate of patients who had the best effect with CR or PR during the treatment was 12.5%(9/72). Patients who were dependent on red-blood-cell transfusions and platelet transfusions at baseline became transfusion independent were 46.3%(19/41)and 41.2% (7/17), respectively. The median time of treatment was 6 cycles, and the median OS was 16.1 months (95%CI 10.9-20.6 months). For 36 patients(50%)received treatment at ≥6 cycles, and the median OS was 22.3 months(95%CI 16.1- not evaluative). Most common grade Ⅲ-Ⅳ hematologic treatment-emergent adverse events were neutropenia(55%), leukopenia(47%), and thrombocytopenia(61%). Pharmacokinetic profiles were similar for generic and original azacitidine in Chinese patients. Conclusion: Generic azacitidine treatment was favorable and safe and can be used as a standard treatment for patients with higher-risk MDS. 目的: 评估国产阿扎胞苷治疗较高危骨髓增生异常综合征(myelodysplastic syndromes, MDS)的疗效、安全性及药代动力学特征。 方法: 2013年10月至2016年10月国内10家中心共纳入72例符合入排标准的较高危MDS患者接受国产阿扎胞苷75 mg·m(-2)·d(-1),皮下注射,持续7 d治疗,4周为1个周期,至少治疗6个周期。药代动力学试验采血为单次给药第1天进行。 结果: 治疗6个周期或6个周期以前终止用药时疗效评估数据显示,总缓解率[完全缓解(CR)+部分缓解(PR)]为6.9%(5/72),治疗期间最佳疗效为CR或PR的患者比例为12.5%(9/72)。治疗期间脱离红细胞和血小板输血依赖的患者分别为46.3%(19/41)和41.2%(7/17)。72例患者中位治疗时间为6个周期,中位总生存(OS)期16.1(95%CI 10.9~20.6)个月,其中治疗≥6个周期患者36例(50%),中位OS期22.3(95%CI 16.1~不可评估)个月。治疗中最常见的Ⅲ~Ⅳ级血液学不良事件为中性粒细胞减少(55%)、白细胞减少(47%)和血小板减少(61%)。药代动力学行为和参数与原研中国数据基本一致。 结论: 接受国产阿扎胞苷标准方案治疗疗效肯定,安全可靠,药代动力学参数与原研阿扎胞苷一致,可作为较高危MDS患者的标准治疗药物。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao HG, Liu F, Qin TJ, et al. [Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33190437. doi:10.3760/cma.j.issn.0253-2727.2020.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。